F

Florida Retina Institute | North Florida - Jacksonville Southside

Research site

(Unclaimed)

Location

8786 Perimeter Park Boulevard, Jacksonville, Florida, United States of America

Site insights

Top conditions

Top treatments

KUS121

Aflibercept

ONL1204

BI 771716

BI 764524

Parent organization

This site is a part of Florida Retina Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Enrolling

Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema

Drug: Aflibercept 8 mg

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) (GION)

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based th...

Enrolling

Central Retinal Artery Occlusion

Drug: KUS121 high dose

Drug: Sham procedure

Locations recently updated

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling

Diabetic Retinopathy

Drug: BI 764524

Drug: Aflibercept (Eylea®) - US only